Tandem Diabetes Care Inc. (TNDM)

Tandem Diabetes launches Control-IQ+ technology commercially in the United States. Control-IQ+ is compatible with t:slim X2 insulin pump and Tandem Mobi System.

SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced the United States commercial launch...

A robust product innovation and several strategic developments raise investors' optimism for Tandem Diabetes.

Tandem Diabetes Care, Inc. released its Q4 and full-year 2024 earnings after the bell yesterday, and the market has given the stock the thumbs down. Shares are down >30% in trading today, despite a be...

Tandem Diabetes' Q4 top and bottom lines lag their respective estimate. However, the company experiences strong sales growth both in and outside the United States.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Susan Morrison - Executive Vice President & Chief Administrative Officer Jo...

While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key m...

Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.27 per share a year ago.

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter and fiscal year e...

Evaluate the expected performance of Tandem Diabetes Care (TNDM) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of it...